Perjeta Regimen Cuts Death Risk by 17% in HER2+ Breast Cancer
Roche, the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support Unit and Frontier Science Foundation, announced today statistically significant final overall…
Read More...
Read More...
